Get the Stockscreener App
0.00
100.00%
-0.0002
Effector Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0002
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$675.00K
Net Income/Loss:
$-34.63M
P/E Ratio:
0.00
EPS:
-13.3158
Net Cash Flow:
$-29.28M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-99.78%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.0002
Effector Therapeutics Inc Stock (EFTR) Company Profile
Name
Effector Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare EFTR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EFTR
Effector Therapeutics Inc
|
0.00 | 0 | 675.00K | -34.63M | -29.28M | -13.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Effector Therapeutics Inc Stock (EFTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-22 | Downgrade | Stifel | Buy → Hold |
| Nov-09-21 | Upgrade | Stifel | Hold → Buy |
| Oct-12-21 | Initiated | Credit Suisse | Outperform |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Sep-20-21 | Initiated | Stifel | Hold |
| Sep-13-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Effector Therapeutics Inc Stock (EFTR) Latest News
EFTR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CapEx per share of eFFECTOR Therapeutics Inc – MUN:LWK - TradingView
Stock List: Research Stocks from Around the World - GuruFocus
MBX Biosciences, Inc. Announces CFO Changes - marketscreener.com
Reprogramming The Tumor Microenvironment Bringing A Metabolic Checkpoint Therapy Into The Clinic - Clinical Leader
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
ZIMCF Stock Price, News & Analysis - Stock Titan
Indian American Premal Patel joins Elephas Biosciences as CMO - The American Bazaar
Non-covid mRNA Vaccine and Therapeutics Market Exclusive Report on the Latest Revenue and Future Scope - openPR.com
Head to Head Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus eFFECTOR Therapeutics (NASDAQ:EFTR) - Defense World
Barclays Forecasts Strong Price Appreciation for Lloyds Banking Group (LON:LLOY) Stock - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is eFFECTOR Therapeutics Inc. (LWK) stock undervalued at current price2025 Historical Comparison & Capital Protection Trade Alerts - ulpravda.ru
Is eFFECTOR Therapeutics Inc. (LWK) stock expanding market penetrationTrade Analysis Summary & High Yield Stock Recommendations - Улправда
ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM - Morningstar
WeRide (NASDAQ:WRD) Now Covered by Analysts at CLSA - Defense World
PowerFleet (NASDAQ:AIOT) Given Outperform Rating at Barrington Research - Defense World
Big Rock Brewery (TSE:BR) Shares Cross Below 50 Day Moving Average – What’s Next? - Defense World
eFFECTOR Therapeutics (NASDAQ:EFTR) and Synaptogenix (NASDAQ:TAOX) Head to Head Review - Defense World
Can eFFECTOR Therapeutics Inc. (LWK) stock expand revenue streamsTrade Entry Report & Weekly Watchlist for Consistent Profits - Улправда
Is eFFECTOR Therapeutics Inc. (LWK) stock vulnerable to rate hikesTrade Volume Report & Stock Market Timing Techniques - DonanımHaber
PD-1 and PD-L1 Inhibitors Market expected to Witness Huge Revenue Growth to 2034 - openPR.com
Why eFFECTOR Therapeutics Inc. (LWK) stock gets analyst attentionInsider Buying & AI Enhanced Trading Signals - Newser
Is eFFECTOR Therapeutics Inc. (LWK) stock positioned for secular growth2025 Market Outlook & Long Hold Capital Preservation Tips - Newser
Why eFFECTOR Therapeutics Inc. (LWK) stock remains top ratedWeekly Stock Recap & Daily Profit Maximizing Tips - Newser
Is eFFECTOR Therapeutics Inc. (LWK) stock resilient in recession scenariosMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Why eFFECTOR Therapeutics Inc. (LWK) stock is listed among top recommendations2025 Technical Patterns & Risk Managed Investment Signals - Newser
What consensus target says about eFFECTOR Therapeutics Inc. (LWK) stockJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
How dovish Fed policy supports eFFECTOR Therapeutics Inc. (LWK) stockJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
eFFECTOR Therapeutics, Inc. (EFTR) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
eFFECTOR Therapeutics, Inc. (EFTR) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How eFFECTOR Therapeutics Inc. (LWK) stock gains from tech spending2025 Short Interest & Fast Gaining Stock Reports - newser.com
Wall Street indexes jump as bets on rate cut increase, Nvidia gains on report - marketscreener.com
eFFECTOR Therapeutics (NASDAQ:EFTR) versus Evotec (OTCMKTS:EVTCY) Head to Head Review - Defense World
Major corporations shift listings to Nasdaq amid growing tech focus - marketscreener.com
Why eFFECTOR Therapeutics Inc. (LWK) stock attracts wealthy investorsAnalyst Downgrade & Safe Capital Preservation Plans - newser.com
Will eFFECTOR Therapeutics Inc. (LWK) stock justify high valuationJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Effector Therapeutics Inc Stock (EFTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Cap:
|
Volume (24h):